4-氯-6-肼基嘧啶 | 5767-35-1

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4-氯-6-肼基嘧啶
• 英文名称: 4-chloro-6-hydrazinopyrimidine
• 英文别名: 4-chloro-6-hydrazinylpyrimidine；(6-chloropyrimidin-4-yl)hydrazine；6-chloro-4-hydrazinopyrimidine
• CAS: 5767-35-1
• 化学式: C₄H₅ClN₄
• mdl: MFCD01646095
• 分子量: 144.564
• InChiKey: NYXYZCSAJZLFEH-UHFFFAOYSA-N

物化性质

• 熔点：
  164-165 °C
• 沸点：
  254.8±50.0 °C(Predicted)
• 密度：
  1.63±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.8
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090
• 包装等级：
  III
• 危险类别：
  6.1
• 危险性防范说明：
  P261,P264,P270,P271,P280,P302+P352,P304+P340,P310,P330,P361,P403+P233,P405,P501
• 危险品运输编号：
  2811
• 危险性描述：
  H301,H311,H331
• 储存条件：
  -20°C下，应避光保存在惰性气体环境中。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Chloro-6-hydrazinopyrimidine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Chloro-6-hydrazinopyrimidine
CAS number: 5767-35-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C4H5ClN4
Molecular weight: 144.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-氯-6-肼基嘧啶 在 palladium on activated charcoal ammonium formate 作用下， 以 甲醇 为溶剂， 反应 15.0h， 生成 4-肼基嘧啶
  参考文献：
  名称：

  Azinyl and Diazinyl Hydrazones Derived from Aryl N-Heteroaryl Ketones:  Synthesis and Antiproliferative Activity^,

  摘要：

  A series of N-heteroaryl hydrazones derived from aryl N-heteroaryl or bis-N-heteroaryl methanones was prepared in search for potential novel antitumor agents. The stereochemistry of these compounds was established by means of NMR spectroscopy. Antiproliferative activity was determined in a panel of human tumor cell Lines (CCRF-CEM, Burkitt's lymphoma, HeLa, ZR-75-1, HT-29, and MEXF 276L) in vitro. Generally, the new compounds were found to be more patent (IC(50) = 0.011-0.436 mu M) than the ribonucleotide reductase inhibitor hydroxyurea (IC(50) = 140 mu M) Most of the compounds exhibited the highest activity against Burkitt's lymphoma with an IC(50) Of 0.011-0.035 mu M. [(14)C]Cytidine incorporation into DNA was quantitated for selected hydrazones (Z-A, E-1, Z-3, Z-4, E-5, Z-5, E-13, E-18, Z-19, Z-24, and E-26) as a measure of the inhibition of-ribonucleotide reductase in Burkitt's lymphoma cells. The E-configurated compounds were found to inhibit [(14)C]cytidine incorporation to a greater extent (IC(50) = 0.67-5.05 mu M) than the Z-isomers (IC(50) = 7.20 to > 10 mu M). Principal component analysis of the IC(50) values obtained for inhibition of cell proliferation revealed that the cell lines tested can be grouped into three main families showing different sensitivities toward the compounds in our series [(i) CCRF-CEM, Burkitt's lymphoma, and Hela; (ii) HT-29; and (iii) MEXF 276 L].

  DOI：

  10.1021/jm970255w
• 作为产物：
  描述：

  4,6-二氯嘧啶 在 一水合肼 作用下， 反应 2.0h， 生成 4-氯-6-肼基嘧啶
  参考文献：
  名称：

  8-Bromo-7-氯[1,2,4]三唑并[4,3-c]嘧啶的合成，它们的环重排为[1,5-c]类似物和进一步多样化

  摘要：

  摘要 通过溴介导醛衍生的azo的氧化环化反应制得8-Bromo-7-氯[1,2,4]三唑并[4,3- c ]嘧啶。通过单晶X射线分析明确地证实了一种这样的产物的结构。尽管C-5未取代的1,2,4-三唑并[4,3- c ]嘧啶化学型在环境条件下极易发生环异构化，但发现C-5取代的类似物非常稳定，可以纯净地分离形成。尽管如此，它们仍然可以转化为1,2,4-三唑[1,5- c嘧啶通过碱或酸促进的Dimroth重排。嘧啶核上卤素官能团的存在使产品可用作易于多样化的通用合成中间体，钯催化的Kumada交叉偶联和Buchwald-Hartwig胺化以及直接的芳族取代证明了这一点。 通过溴介导醛衍生的azo的氧化环化反应制得8-Bromo-7-氯[1,2,4]三唑并[4,3- c ]嘧啶。通过单晶X射线分析明确地证实了一种这样的产物的结构。尽管C-5未取代的1,2,4-三唑并[4,3- c ]嘧啶化学型

  DOI：

  10.1055/s-0034-1378453

文献信息

• [EN] HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES<br/>[FR] COMPOSÉS HÉTÉROARYLE-TRIAZOLE UTILISÉS COMME PESTICIDES
  申请人：BAYER AG

  公开号：WO2021165195A1

  公开（公告）日：2021-08-26

  The present invention relates to novel heteroaryl-triazole compounds of the general formula (I), in which the structural elements X, Y, R1, R2, R3a, R3b, R4 and R5 have the meaning given in the description, to formulations and compositions comprising such compounds and for their use in the control of animal pests including arthropods and insects in plant protection and to their use for control of ectoparasites on animals.

  本发明涉及一般式（I）的新异芳基-三唑化合物，其中结构元素X、Y、R1、R2、R3a、R3b、R4和R5的含义如描述中所给，以及包含这些化合物的配方和组合物，用于控制包括节肢动物和昆虫在内的动物害虫，用于植物保护，并用于控制动物体表寄生虫。
• [EN] GPR52 MODULATOR COMPOUNDS<br/>[FR] COMPOSÉS MODULATEURS DE GPR52
  申请人：HEPTARES THERAPEUTICS LTD

  公开号：WO2021090030A1

  公开（公告）日：2021-05-14

  The disclosures herein relate to novel compounds of Formula (1): (1) and salts thereof, wherein R1, Q, X, Y and Z are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with GPR52 receptors.

  本公开涉及式(1)的新颖化合物： (1)及其盐，其中R1、Q、X、Y和Z的定义如本文中所述，以及它们用于治疗、预防、改善、控制或降低与GPR52受体相关的疾病的风险。
• [EN] ErbB RECEPTOR INHIBITORS AS ANTI-TUMOR AGENTS<br/>[FR] INHIBITEURS DE RÉCEPTEURS ERBB UTILISÉS COMME AGENTS ANTITUMORAUX
  申请人：SUZHOU ZANRONG PHARMA LTD

  公开号：WO2021179274A1

  公开（公告）日：2021-09-16

  Provided herein are novel compounds as inhibitors of type I receptor tyrosine kinases, the pharmaceutical compositions comprising one or more of the compounds and salts thereof as an active ingredient, and the use of the compounds and salts thereof in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals and especially in humans.

  本文提供了作为I型受体酪氨酸激酶抑制剂的新化合物，包括其中一种或多种化合物及其盐作为活性成分的药物组合物，以及在哺乳动物，尤其是人类中治疗高增殖性疾病（如癌症和炎症）中使用这些化合物及其盐的用途。
• SUBSTITUTED DIHYDROPYRAZOLONES AND THEIR USE
  申请人：Jeske Mario

  公开号：US20090269420A1

  公开（公告）日：2009-10-29

  The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and haematological diseases and kidney diseases, and for promoting wound healing.

  本申请涉及新颖的取代二氢吡唑酮衍生物，其制备方法，它们用于治疗和/或预防疾病的用途，以及用于制备治疗和/或预防疾病的药物，特别是心血管和血液疾病、肾脏疾病以及促进伤口愈合的用途。
• 一种二氢吡唑啉酮类化合物的晶型及其制备方法
  申请人：中国医药研究开发中心有限公司

  公开号：CN111825689B

  公开（公告）日：2023-05-05

  本发明涉及一种二氢吡唑啉酮类化合物的晶型及其制备方法。具体而言，本发明涉及1‑(6‑(2‑氧杂‑8‑氮杂螺[4.5]癸烷‑8‑基)嘧啶‑4‑基)‑4‑(1H‑1,2,3‑三唑‑1‑基)‑1H‑吡唑‑5‑醇钠的A晶型和B晶型。其通过将2‑(6‑(2‑氧杂‑8‑氮杂螺[4.5]癸烷‑8‑基)嘧啶‑4‑基)‑4‑(1H‑1,2,3‑三唑‑1‑基)‑1,2‑二氢‑3H‑吡唑‑3‑酮在有机溶剂中制成钠盐并析晶获得。其可以用于预防和/或治疗与PHD活性相关的疾病。